TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03906513

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: OMK2
Description: OMK2 (including citicoline 2%, high molecular weight hyaluronic acid 0.2%, cyanocobalamin and 0.01% BAK, Omikron Italia SRL) is a Class IIa device CE marked registered in Medical Devices Database of Italian Ministry of Health (identification number of registration: 1170558).

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: OMK2
Description: OMK2 (including citicoline 2%, high molecular weight hyaluronic acid 0.2%, cyanocobalamin and 0.01% BAK, Omikron Italia SRL) is a Class IIa device CE marked registered in Medical Devices Database of Italian Ministry of Health (identification number of registration: 1170558).
Study: NCT03938064

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Prontogest 400 mg vaginal pessaries
Description: natural progesterone in the form of vaginal suppositories 400 mg

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Prontogest 400 mg vaginal pessaries
Description: natural progesterone in the form of vaginal suppositories 400 mg
Study: NCT02762383

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Peginterferon Alfa-2
Description: Peginterferon alfa-2a will be administered as 90 micrograms (mcg) via subcutaneous (SC) injection once weekly.
Study: NCT00586079

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Deep brain stimulation surgery.
Description: Deep brain stimulation surgery.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Deep brain stimulation surgery.
Description: Deep brain stimulation surgery.
Study: NCT02040987

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD3293
Description: AZD3293 oral solution - one single dose (low dose).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD3293
Description: AZD3293 oral solution - one single dose (high dose).

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo oral solution - one single dose

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Moxifloxacin
Description: Moxifloxacin tablet - one single dose
Study: NCT03806465

Intervention type: OTHER
Intervention: Feasibility survey
Description: A survey questionnaire will be administered at each household. At the baseline household survey, each child aged less than 5 years will be tested for malaria using a rapid malaria test.

Intervention type: OTHER
Intervention: Sentinel hospital surveillance
Description: Cerebrospinal samples will be collected from all children hospitalised and suspected of having meningitis.
Study: NCT01802476

Intervention type: DRUG
Group type: OTHER
Intervention: Intravenous Formulation of PD-0332991
Description: Treatment B consists of a 1000 mL intravenous infusion of 50 mg of PD-0332991 administered over 4 hours at a constant rate.
Study: NCT00392314

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: PET/CT post 2 cycles of chemotherapy
Description: sintigraphy with PET/CT following 2 cycles of chemotherapy on day 12-14 following chemotherapy

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: PET/CT post 2 cycles of chemotherapy
Description: sintigraphy with PET/CT following 2 cycles of chemotherapy on day 12-14 following chemotherapy
Study: NCT03806465

Intervention type: OTHER
Intervention: Community mortality surveillance
Description: A verbal autopsy will be performed
Study: NCT02755454

Intervention type: DEVICE
Group type: OTHER
Intervention: Perfusion CT Imaging
Study: NCT01306721

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: fexofenadine HCL (M016455)
Description: Pharmaceutical form:tablet Route of administration: oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: fexofenadine HCL (M016455)
Description: Pharmaceutical form:tablet Route of administration: oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: fexofenadine HCL (M016455)
Description: Pharmaceutical form:tablet Route of administration: oral

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: pseudoephedrine
Description: Pharmaceutical form:tablet~Route of administration: oral
Study: NCT03703141

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: sucralose 48 mg (splenda)/day for ten weeks
Description: volunteers will take sucralose or placebo daily for 70 days

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: sucralose 48 mg (splenda)/day for ten weeks
Description: volunteers will take sucralose or placebo daily for 70 days

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: sucralose 48 mg (splenda)/day for ten weeks
Description: volunteers will take sucralose or placebo daily for 70 days
Study: NCT02057302

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Xuezhikang capsule
Study: NCT00804414

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SBG
Description: Solution for topical use

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Comparator
Description: Solutin for topical use
Study: NCT01705951

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Resistance Training (RT)
Description: Resistance Training program 3x/week at 60 minutes per session for 12 weeks.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Resistance Training (RT)
Description: Resistance Training program 3x/week at 60 minutes per session for 12 weeks.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Nicotine Replacement Therapy (NRT)
Description: Nicotine patch for 12 weeks (21mg, 14mg, 7mg.) and referral to California Smoker's Helpline for 6 sessions of smoking cessation counseling.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Nicotine Replacement Therapy (NRT)
Description: Nicotine patch for 12 weeks (21mg, 14mg, 7mg.) and referral to California Smoker's Helpline for 6 sessions of smoking cessation counseling.
Study: NCT01561885

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Pathway-Based Care
Description: Patients who are randomly allocated to Pathway Care will be treated by the Pathway Clinical Teaching Unit as well as other collaborative healthcare professionals (pharmacists, nurses, health educators, nutritionists, and social workers). The Pathway Care physicians will have access to the Clinical Care Plan on the QuadraMed, which is a detailed, organized, day-to-day treatment plan that includes pre-set orders and medications. Physicians for the patients on Usual Care will not have access to this information, and the collaborative healthcare will only be provided upon consultation.
Study: NCT00359385

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Alendronate 70mg weekly
Description: 70mg weekly

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Alendronate 70mg weekly
Description: 70mg weekly
Study: NCT03739333

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: 11C-Methionine PET-MRI
Description: Implementation 11C-Methionine PET-MRI performed for each patient in one place (department of nuclear medicine of Hospices Civils de Lyon). The 11C-Methionine PET-MRI will be performed after radiochemotherapy in patients with MRI suspicious of pseudoprogression.
Study: NCT02003664

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Baclofen ER
Description: Comparison of Baclofen ER to placebo using a 2 to 1 chance of receiving Baclofen ER, the medication

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Comparison of placebo to Baclofen ER using a 1 in 3 chance of receiving placebo
Study: NCT04506359

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Experimental Group
Description: The Ex group is COPSCCP+ UC+ case manager care. In this group, a 6-month intervention providing for each time while subject visit their chest surgeon(s) in the OPD (from the first time before hospital discharge/T1).
Study: NCT00385697

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Teplizumab
Description: Daily IV dosing for 14 days, repeated at Week 26

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Teplizumab
Description: Daily IV dosing for 14 days, repeated at Week 26

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Teplizumab
Description: Daily IV dosing for 14 days, repeated at Week 26

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Teplizumab
Description: Daily IV dosing for 14 days, repeated at Week 26

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Daily IV dosing for 14 days, repeated at Week 26
Study: NCT01811628

Intervention type: BEHAVIORAL
Intervention: Questionnaire
Description: Questionnaire completion taking about 10-15 minutes.

Intervention type: BEHAVIORAL
Intervention: Interview
Description: Audio-recorded interview that will last about 1 hour.
Study: NCT01909947

Intervention type: OTHER
Intervention: Cardiorespiratory signal acquisition
Description: Cardiorespiratory signals will measure heart rate (using electrocardiography), chest and abdominal movements (using respiratory inductance plethysmography) and oxygen saturation (using pulse oximetry). Data will be acquired during 2 recording periods:~1. A 60-minute period while the infant receives any mode of conventional mechanical ventilation~2. A 5-minute period prior to extubation while the mode of ventilation is switched to endotracheal tube CPAP (Continuous Positive Airway Pressure), so that the respiratory pattern will be controlled by the infant
Study: NCT04659200

Intervention type: DIAGNOSTIC_TEST
Intervention: Venous blood was collected for biochemistry testing.
Description: For the measurement of blood tests, 10 ml of blood samples were taken from the right forearm veins with a syringe.

Intervention type: DIAGNOSTIC_TEST
Intervention: Venous blood was collected for biochemistry testing.
Description: For the measurement of blood tests, 10 ml of blood samples were taken from the right forearm veins with a syringe.
Study: NCT01705223

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: DNA vaccine
Description: 4mg/dose, three doses at week 0,4,8

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: DNA vaccine
Description: 4mg/dose, three doses at week 0,4,8

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: DNA vaccine
Description: 4mg/dose, three doses at week 0,4,8

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: DNA vaccine prime with the addition of electroporation
Description: 4mg/dose, three doses at week 0,4,8

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: rTV boost
Description: at week 16

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: rTV boost
Description: at week 24

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: rTV boost
Description: at week 24

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: rTV boost
Description: at week 32
Study: NCT01325818

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: pravastatin, rosuvastatin
Description: 1. Active Comparator Intervention: Drug: pravastatin 10mg/day or 20mg/day~2. Active Comparator Intervention: Drug: rosuvastatin 20mg/day
Study: NCT03071731

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Bronchodilators
Description: Administration of a nebulized combination of bronchodilators before the administration of a functional test.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebos
Description: Administration of a nebulized placebo before the administration of a functional test

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebos
Description: Administration of a nebulized placebo before the administration of a functional test
Study: NCT02895750

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin
Description: Metformin extended release tablets (Glucophage 500 mg; 750 mg; 1,000 mg) administrated during 6 to 12 weeks (CKD1 and 3B, respectively)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin
Description: Metformin extended release tablets (Glucophage 500 mg; 750 mg; 1,000 mg) administrated during 6 to 12 weeks (CKD1 and 3B, respectively)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin
Description: Metformin extended release tablets (Glucophage 500 mg; 750 mg; 1,000 mg) administrated during 6 to 12 weeks (CKD1 and 3B, respectively)
Study: NCT00427297

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZT/3TC/NVP (zidovudine/lamivudine/nevirapine)
Description: First line regimen

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: d4T/3TC/NVP (stavudine/lamivudine/nevirapine)
Description: First line regimen
Study: NCT01306721

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pseudoephedrine
Description: Pharmaceutical form:tablet~Route of administration: oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pseudoephedrine
Description: Pharmaceutical form:tablet~Route of administration: oral
Study: NCT00427297

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: AZT/3TC/ABC (zidovudine/lamivudine/abacavir)
Description: First line regimen

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: d4T/3TC/ABC (stavudine/lamivudine/abacavir)
Description: First line regimen For children who have anaemia(Hb of\<8g/dl), AZT will be substituted for d4T.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ddI/ABC/LPV/r (didanosine/abacavir/lopinavir-ritonavir)
Description: Second line regimen

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ABC/ ddI or TDF / NVP or EFV (abacavir / didanosine or tenofovir / nevirapine or efavirenz)
Description: Second line regimen - Among children randomized to NVP sparing HAART, who will be initiated on a regimen containing lopinavir/ritonavir, zidovudine and lamivudine will be substituted with abacavir and didanosine or tenofovir (TDF) and lopinavir/ ritonavir will be replaced with nevirapine or efavirenz (EFV) in case of treatment failure of the LPV/r containing regimen.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABC/3TC/NVP (abacavir/lamivudine/nevirapine)
Description: First line regimen
Study: NCT04989634

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Intensive dietary and weight management
Description: health education , nutritional analysis and individualized dietary guidance

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Standard care
Description: Standard prenatal education on diet, nutrition and physical activity
Study: NCT04018040

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Lacto-ovo vegetarian diet
Description: Lacto-ovo vegetarian diet inclusive of dairy and eggs
Study: NCT02160522

Intervention type: DEVICE
Intervention: Cuffed ETT
Description: Measurement of the cuff pressure on an endotracheal tube and lower pressure to a safe range if it is elevated.
Study: NCT02106663

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Circumferential Pulmonary Vein Ablation
Description: Contiguous ablation lesions will be performed to encircle the two left and right pulmonary veins (PVs) of the left atrium, guided by 3D electroanatomic mapping. After completion of the circumferential ablation, PV isolation will be confirmed by the mapping catheter, and further focal ablation performed as required until electrical PV isolation is confirmed.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Segmental Pulmonary Vein Isolation
Description: Electrical potentials recorded in the pulmonary vein (PV) ostium using a circular mapping catheter, representing electrical connections between the left atrium and PVs will be ablated at or just proximal to the PV ostium in the PV antrum. Ablation will be performed segmentally at multiple sites guided by the mapping catheter until mapping demonstrates elimination of all PV potentials.
Study: NCT02528890

Intervention type: OTHER
Intervention: vaginal/anal swab for GBS from all participants
Description: All eligible pregnant women, who meet the inclusion criteria and gave their informed consent to participate in the study has to complete a questionnaire and have a vaginal / anal swab taken to identify positive GBS carriers by PCR (polymerase chain reaction) test.
Study: NCT00689559

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD3480
Description: AZD3480 capsules qd, oral, 22 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo qd, 12 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aripiprazole
Description: single dose on day 5

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aripiprazole
Description: single dose on day 5
Study: NCT00621595

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: USDA School Breakfast
Description: Breakfast containing 340 calories, 57 g carbohydrate, 14 g protein, 6 g fat.
Study: NCT01131065

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hepatitis B immune globulin
Description: Daily doses of 10,000 IU of intravenous hepatitis B immune globulin during the first week post-transplantation (anhepatic phase + days 1-7), followed by weekly and monthly doses of 5,000 IU during weeks 2,3, and 4 and months 2,3,4,5,6,7,8,9,10,11 and 12, respectively.
Study: NCT00478114

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: sorafenib
Description: sorafenib in the patients with advanced Renal Cell Carcinoma
Study: NCT03441607

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: mHACMb
Description: Active ingredient

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: inactive ingredient
Study: NCT02123836

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: NK cells
Description: 7 days of preparatory treatment are given before the NK cell infusion. Chemotherapy will be given over 6 days. This chemotherapy will promote donor NK cells engraftment. After which, a drug called Interleukin-2 (IL-2) will be given as an injection just under the skin three times per week for at least 2 weeks (total of 6 doses). This treatment is used to help keep the donor NK cells alive.~Blood cells will be collected from an eligible and suitable family donor 10 days before infusion. The collection sample will be processed to remove red blood cells and as many T-cells as possible. T-cells from the donor might cause these donor cells to attack the body, usually the skin, liver, and intestines.~NK cells will be activated in the National University Hospital lab and ready for infusion on Day 0.~The NK cells will then be infused into the vein, through a peripheral catheter.
Study: NCT06153186

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Flunarizine Hydrochloride
Description: Flunarizine tablet
Study: NCT03796442

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: AVR with AVALUS
Description: aortic valve replacement with AVALUS bioprosthesis

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: AVR with CEPME
Description: aortic valve replacement with Carpentier-Edwards Perimount Magna Ease bioprosthesis
Study: NCT00131365

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ExAblate 2000
Study: NCT01258179

Intervention type: OTHER
Intervention: Analysis of PSP and PAP from venous blood samples
Description: to analyse the peri-operative expression of pancreatic stone protein in surgical patients following major abdominal surgery

Intervention type: OTHER
Intervention: Analysis of PSP and PAP from venous blood samples
Description: to analyse the peri-operative expression of pancreatic stone protein in surgical patients following major abdominal surgery
Study: NCT00732758

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Vitamin D3 1000 IU
Description: Vitamin D3 1000 IU Tablet once daily for 6 months

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Tablet
Description: Placebo Tablet once daily for 6 months
Study: NCT04376086

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Epidural anesthesia
Description: Segmental epidural analgesia

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: general anesthesia
Description: general anesthesia
Study: NCT02757937

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Health & Wellness Website
Description: Educational website for patients with chronic disease (i.e., Type 2 diabetes, asthma, high blood pressure, high cholesterol). The website is a free interactive resource to help patients manage their health condition(s) each day and to help them achieve their goals. It is a multichannel health and wellness platform to help patients adhere to their treatment and care plans between office visits.

Intervention type: OTHER
Group type: OTHER
Intervention: Control Arm
Description: Continue with standard diabetes care without getting access to the intervention website.
Study: NCT03653377

Intervention type: OTHER
Intervention: Self administrated questionnaire
Description: Questionnaires are distributed to patients with their parents during their visit to the CF center.
Study: NCT02216149

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: S-1
Description: S-1 25 mg/m2/day BID d1-14, oxaliplatin injection 130 mg/m2 D1 every 3 weeks

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Capecitabine
Description: capecitabine 2000 mg/m2/day divided in 2 daily doses d1-14, oxaliplatin injection 130 mg/m2 D1 every 3 weeks

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oxaliplatin
Description: Oxaliplatin 130 mg/m2 D1 every 3 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxaliplatin
Description: Oxaliplatin 130 mg/m2 D1 every 3 weeks
Study: NCT01306721

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: fexofenadine HCL matching placebo
Description: Pharmaceutical form:tablet~Route of administration: oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: fexofenadine HCL matching placebo
Description: Pharmaceutical form:tablet~Route of administration: oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: fexofenadine HCL matching placebo
Description: Pharmaceutical form:tablet~Route of administration: oral

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: pseudoephedrine matching placebo
Description: Pharmaceutical form:tablet~Route of administration: oral
Study: NCT02892513

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Percutaneous auricular neurostimulation
Description: The Bridge device (manufactured by Key Electronics \[Jeffersonville, IN, USA\] and distributed by Innovative Health Solutions \[Versailles, IN, USA\]) provides continual neurostimulation for five days with alternating current.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham percutaneous auricular neurostimulation
Description: Identical in appearance to active, device, but no stimulation will be given.
Study: NCT00456508

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ecallantide
Description: solution for SC injection, one 30 mg dose per HAE attack